Exploiting directed evolution for the discovery of biologicals.
Protein-based drugs offer unique advantages over small-molecule drugs in terms of both discovery and therapeutic use. The advent of recombinant DNA technology enabled the production of recombinant proteins and the generation of partially or fully human monoclonal antibodies, and continued developments in molecular biology have provided powerful approaches to generate improved proteins with more drug-like features. In this review, the benefits of using an evolutionary approach to biologicals drug discovery are discussed, with emphasis on the use of in vitro evolution technologies, such as ribosome display.